Didier Ducloux

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9020056/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants. Kidney International, 2020, 98, 1549-1558.	5.2	213
2	Serum Total Homocysteine and Cardiovascular Disease Occurrence in Chronic, Stable Renal Transplant Recipients. Journal of the American Society of Nephrology: JASN, 2000, 11, 134-137.	6.1	178
3	One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation. Transplantation, 2016, 100, 391-399.	1.0	157
4	Relevance of Toll-like receptor-4 polymorphisms in renal transplantation. Kidney International, 2005, 67, 2454-2461.	5.2	150
5	Predicting coronary heart disease in renal transplant recipients: A prospective study. Kidney International, 2004, 66, 441-447.	5.2	149
6	Drug-resistant cytomegalovirus in transplant recipients: a French cohort study. Journal of Antimicrobial Chemotherapy, 2010, 65, 2628-2640.	3.0	141
7	C-reactive protein and cardiovascular disease in peritoneal dialysis patients. Kidney International, 2002, 62, 1417-1422.	5.2	131
8	One‥ear Postâ€Transplant Weight Gain is a Risk Factor for Graft Loss. American Journal of Transplantation, 2005, 5, 2922-2928.	4.7	113
9	CD4 LYMPHOCYTOPENIA AS A RISK FACTOR FOR SKIN CANCERS IN RENAL TRANSPLANT RECIPIENTS. Transplantation, 1998, 65, 1270-1272.	1.0	112
10	Humoral response after 3 doses of the BNT162b2 mRNA COVID-19 vaccine in patients on hemodialysis. Kidney International, 2021, 100, 702-704.	5.2	99
11	Prolonged CD4 T Cell Lymphopenia Increases Morbidity and Mortality after Renal Transplantation. Journal of the American Society of Nephrology: JASN, 2010, 21, 868-875.	6.1	87
12	IMPact of the COVID-19 epidemic on the moRTAlity of kidney transplant recipients and candidates in a French Nationwide registry sTudy (IMPORTANT). Kidney International, 2020, 98, 1568-1577.	5.2	85
13	Posttransplant Diabetes Mellitus and Atherosclerotic Events in Renal Transplant Recipients: A Prospective Study. Transplantation, 2005, 79, 438-443.	1.0	82
14	MYCOPHENOLATE MOFETIL-INDUCED VILLOUS ATROPHY. Transplantation, 1998, 66, 1115-1116.	1.0	80
15	CD4 Cell Lymphopenia and Atherosclerosis in Renal Transplant Recipients. Journal of the American Society of Nephrology: JASN, 2003, 14, 767-772.	6.1	77
16	MYCOPHENOLATE MOFETIL IN RENAL TRANSPLANT RECIPIENTS WITH CYCLOSPORINE-ASSOCIATED NEPHROTOXICITY. Transplantation, 1998, 65, 1504-1506.	1.0	76
17	Peritoneal Dialysis Reduces the Number of Hospitalization Days in Heart Failure Patients Refractory to Diuretics. Peritoneal Dialysis International, 2014, 34, 100-108.	2.3	74
18	Uraemia-induced immune senescence and clinical outcomes in chronic kidney disease patients. Nephrology Dialysis Transplantation, 2020, 35, 624-632.	0.7	73

#	Article	IF	CITATIONS
19	Metabolic Syndrome and Atherosclerotic Events in Renal Transplant Recipients. Transplantation, 2007, 83, 1577-1581.	1.0	66
20	RECURRENCE OF HEMOLYTIC-UREMIC SYNDROME IN RENAL TRANSPLANT RECIPIENTS. Transplantation, 1998, 65, 1405-1407.	1.0	66
21	PREVALENCE AND CLINICAL SIGNIFICANCE OF ANTIPHOSPHOLIPID ANTIBODIES IN RENAL TRANSPLANT RECIPIENTS. Transplantation, 1999, 67, 90-93.	1.0	65
22	LONG-TERM TOXICITY OF ANTITHYMOCYTE GLOBULIN INDUCTION MAY VARY WITH CHOICE OF AGENT: A SINGLE-CENTER RETROSPECTIVE STUDY. Transplantation, 2004, 77, 1029-1033.	1.0	63
23	Urinary cytotoxic molecular markers for a noninvasive diagnosis in acute renal transplant rejection*. Transplant International, 2006, 19, 759-768.	1.6	63
24	Cytomegalovirus Exposure and Cardiovascular Disease in Kidney Transplant Recipients. Journal of Infectious Diseases, 2013, 207, 1569-1575.	4.0	63
25	IL-6 Promoter Polymorphism â^174 Is Associated with New-Onset Diabetes after Transplantation. Journal of the American Society of Nephrology: JASN, 2006, 17, 2333-2340.	6.1	59
26	Use of pentoxifylline in membranous nephropathy. Lancet, The, 2001, 357, 1672-1673.	13.7	58
27	Impact of malnutrition–inflammation on the association between homocysteine and mortality. Kidney International, 2006, 69, 331-335.	5.2	57
28	Acquired hypercoagulable state in renal transplant recipients. Thrombosis and Haemostasis, 2004, 91, 646-654.	3.4	54
29	Lymphocyte subsets and assessment of cancer risk in renal transplant recipients. Transplant International, 2002, 15, 393-396.	1.6	51
30	Impact of renal dysfunction on 1-year mortality after acute myocardial infarction. American Heart Journal, 2006, 151, 661-667.	2.7	49
31	ESRD-associated immune phenotype depends on dialysis modality and iron status: clinical implications. Immunity and Ageing, 2018, 15, 16.	4.2	47
32	Pretransplant Serum Vitamin D Levels and Risk of Cancer After Renal Transplantation. Transplantation, 2008, 85, 1755-1759.	1.0	45
33	Cyclosporin withdrawal with concomitant conversion from azathioprine to mycophenolate mofetil in renal transplant recipients with chronic allograft nephropathy: a 2-year follow-up. Transplant International, 2002, 15, 387-392.	1.6	40
34	Preâ€ŧransplant endâ€stage renal diseaseâ€related immune risk profile in kidney transplant recipients predicts postâ€ŧransplant infections. Transplant Infectious Disease, 2016, 18, 415-422.	1.7	39
35	Cytomegalovirus-associated venous thromboembolism in renal transplant recipients: A report of 7 cases. Transplantation, 2004, 77, 597-599.	1.0	37
36	Anti-thymocyte globulins in kidney transplantation: focus on current indications and long-term immunological side effects. Nephrology Dialysis Transplantation, 2017, 32, gfw368.	0.7	34

#	Article	IF	CITATIONS
37	Pretransplant thymic function predicts acute rejection in antithymocyte globulin–treated renal transplant recipients. Kidney International, 2016, 89, 1136-1143.	5.2	31
38	Hyperhomocysteinaemia therapy in haemodialysis patients: folinic versus folic acid in combination with vitamin B6 and B12. Nephrology Dialysis Transplantation, 2002, 17, 865-870.	0.7	30
39	Antiphospholipid antibodies as a risk factor for atherosclerotic events in renal transplant recipients. Kidney International, 2003, 64, 1065-1070.	5.2	30
40	Kidney transplantation in patients with systemic sclerosis: a nationwide multicentre study. Transplant International, 2017, 30, 256-265.	1.6	30
41	Lymphocyte subsets and assessment of cancer risk in renal transplant recipients. Transplant International, 2002, 15, 393-6.	1.6	29
42	Impact of preâ€ŧransplant dialysis modality on postâ€ŧransplant diabetes mellitus after kidney transplantation. Clinical Transplantation, 2011, 25, 794-799.	1.6	28
43	Thymic function, anti-thymocytes globulins, and cancer after renal transplantation. Transplant Immunology, 2011, 25, 56-60.	1.2	26
44	Polyclonal Antithymocyte Globulin and Cardiovascular Disease in Kidney Transplant Recipients. Journal of the American Society of Nephrology: JASN, 2014, 25, 1349-1356.	6.1	25
45	Cyclosporine withdrawal in stable renal transplant recipients after azathioprine-mycophenolate mofetil conversion. Clinical Transplantation, 2000, 14, 561-566.	1.6	24
46	End-Stage Renal Disease-Associated Gut Bacterial Translocation: Evolution and Impact on Chronic Inflammation and Acute Rejection After Renal Transplantation. Frontiers in Immunology, 2019, 10, 1630.	4.8	24
47	Cytomegalovirus exposure, immune exhaustion and cancer occurrence in renal transplant recipients. Transplant International, 2012, 25, 948-955.	1.6	23
48	Incidence, Predictors, and Impact on Six-Month Mortality of Three Different Definitions of Contrast-Induced Acute Kidney Injury After Coronary Angiography. American Journal of Cardiology, 2018, 121, 818-824.	1.6	19
49	Treatment of hyperhomocysteinemia with folic acid reduces oxidative stress in renal transplant recipients. Transplantation, 2002, 73, 663-665.	1.0	19
50	A multicenter, randomized trial of increased mycophenolic acid dose using enteric-coated mycophenolate sodium with reduced tacrolimus exposure in maintenance kidney transplant recipients. Clinical Nephrology, 2012, 77, 126-136.	0.7	19
51	Corticosteroid avoidance in adult kidney transplant recipients under rabbit anti-T-lymphocyte globulin, mycophenolate mofetil and delayed cyclosporine microemulsion introduction. Transplant International, 2010, 23, 313-324.	1.6	17
52	Significant Increase in 1-Year Posttransplant Renal Arterial Index Predicts Graft Loss. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1867-1872.	4.5	16
53	REGEN-Cov antibody combination to prevent COVID-19 infection in kidney transplant recipient without detectable antibody response to optimal vaccine scheme. Kidney International, 2022, 101, 645-646.	5.2	15
54	Influence ofCyclooxygenase-2 (COX-2)Gene Promoter Polymorphism â^'765 on Graft Loss After Renal Transplantation. American Journal of Transplantation, 2009, 9, 2752-2757.	4.7	13

#	Article	IF	CITATIONS
55	Peritoneal dialysis after kidney transplant failure: a nationwide matched cohort study from the French Language Peritoneal Dialysis Registry (RDPLF). Nephrology Dialysis Transplantation, 2019, 34, 858-863.	0.7	13
56	Factors associated with humoral response after BNT162b2 mRNA COVID-19 vaccination in kidney transplant patients. CKJ: Clinical Kidney Journal, 2021, 14, 2270-2272.	2.9	12
57	Posttransplant Immune Activation. Cell Transplantation, 2017, 26, 1601-1609.	2.5	11
58	Temporal trends in living kidney donation in France between 2007 and 2017. Nephrology Dialysis Transplantation, 2021, 36, 730-738.	0.7	11
59	Homocysteine, nutritional status and insulin in renal transplant recipients. Nephrology Dialysis Transplantation, 2002, 17, 1674-1677.	0.7	10
60	Influence of Fractalkine Receptor Gene Polymorphisms V249I-T280M on Cancer Occurrence After Renal Transplantation. Transplantation, 2013, 95, 728-732.	1.0	10
61	Pre-transplant Thymic Function Predicts Is Associated With Patient Death After Kidney Transplantation. Frontiers in Immunology, 2020, 11, 1653.	4.8	10
62	Humoral response after BNT162b2 mRNA COVID-19 vaccination in patients on haemodialysis depends on immune status. CKJ: Clinical Kidney Journal, 2021, 14, 2266-2267.	2.9	10
63	Renal function with delayed or immediate cyclosporine microemulsion in combination with enteric-coated mycophenolate sodium and steroids: results of follow up to $30\hat{a} \in f$ months post-transplant. Clinical Transplantation, 2007, 21, 295-300.	1.6	9
64	TheInterleukin-6Gene Promoter Polymorphism -174 and Atherosclerotic Events in Overweight Transplanted Patients. Journal of Transplantation, 2011, 2011, 1-6.	0.5	9
65	Prevention of Post-Transplant Diabetes Mellitus: Towards a Personalized Approach. Journal of Personalized Medicine, 2022, 12, 116.	2.5	9
66	Alloimmune Responses and Atherosclerotic Disease After Kidney Transplantation. Transplantation, 2015, 99, 220-225.	1.0	8
67	Antithymocyte globulins in renal transplantation—from lymphocyte depletion to lymphocyte activation: The doubled-edged sword. Transplantation Reviews, 2017, 31, 180-187.	2.9	8
68	Plasma cell neoplasia after kidney transplantation: French cohort series and review of the literature. PLoS ONE, 2017, 12, e0179406.	2.5	8
69	Rituximab for recurrence of primary focal segmental glomerulosclerosis after kidney transplantation: Results of a nationwide study. American Journal of Transplantation, 2021, 21, 3021-3033.	4.7	8
70	Clinical Utility of Biochemical Markers for the Prediction of COVID-19â^'Related Mortality in Kidney Transplant Recipients. Kidney International Reports, 2021, 6, 2689-2693.	0.8	8
71	End-Stage Renal Disease-Related Accelerated Immune Senescence: Is Rejuvenation of the Immune System a Therapeutic Goal?. Frontiers in Medicine, 2021, 8, 720402.	2.6	8
72	Late Persistent Positive EBV Viral Load and Risk of Solid Cancer in Kidney Transplant Patients. Transplantation, 2017, 101, 1473-1478.	1.0	7

#	Article	IF	CITATIONS
73	Long-term follow-up of renal transplant recipients treated with losartan for post-transplant erythrosis. Transplant International, 1998, 11, 312-315.	1.6	7
74	Cytomegalovirus infection and chronic graft-versus-host disease are significant predictors of renal failure after allogeneic hematopoietic stem cell transplantation. Haematologica, 2005, 90, 569-70.	3.5	7
75	Cyclosporin withdrawal with concomitant conversion from azathioprine to mycophenolate mofetil in renal transplant recipients with chronic allograft nephropathy: a 2-year follow-up. Transplant International, 2002, 15, 387-92.	1.6	7
76	No Evidence of Association between NOD2/CARD15 Gene Polymorphism and Atherosclerotic Events after Renal Transplantation. Transplantation, 2006, 81, 1212-1215.	1.0	6
77	Lymphocyte Subsets in Renal Transplant Recipients with de novo Genitourinary Malignancies. Urologia Internationalis, 2008, 80, 257-263.	1.3	6
78	Immune reconstitution with two different rabbit polyclonal anti-thymocytes globulins. Transplant Immunology, 2017, 45, 48-52.	1.2	6
79	Effect of adding vildagliptin to insulin in haemodialysed patients with type 2 diabetes: The VILDDIAL study, a randomized, multicentre, prospective study. Diabetes, Obesity and Metabolism, 2020, 22, 978-987.	4.4	6
80	Current vaccine strategies against SARS_CoV-2 only poorly protect kidney transplant recipients. Journal of Infection, 2022, 84, e34-e35.	3.3	6
81	Impact of renal dysfunction and glucometabolic status on one month mortality after acute myocardial infarction. Acute Cardiac Care, 2007, 9, 34-42.	0.2	5
82	Influence of Cyclooxygenase-2 (COX-2) Gene Promoter Polymorphism at Position â^'765 on Skin Cancer after Renal Transplantation. Journal of Investigative Dermatology, 2010, 130, 2134-2136.	0.7	5
83	Regulatory T cells and cancer: an undesired tolerance. Kidney International, 2014, 86, 16-18.	5.2	5
84	Immune phenotype predicts new onset diabetes after kidney transplantation. Human Immunology, 2019, 80, 937-942.	2.4	5
85	Organ Transplantation in Hereditary Fibrinogen A α-Chain Amyloidosis: A Case Series of French Patients. American Journal of Kidney Diseases, 2020, 76, 384-391.	1.9	5
86	New Insights on End-Stage Renal Disease and Healthy Individual Gut Bacterial Translocation: Different Carbon Composition of Lipopolysaccharides and Different Impact on Monocyte Inflammatory Response. Frontiers in Immunology, 2021, 12, 658404.	4.8	5
87	The Case â^£ A female with hyponatremia. Kidney International, 2009, 76, 351-352.	5.2	4
88	The COX-2 gene promoter polymorphism -765 delays CD4 T-cell reconstitution after lymphocyte depletion with antithymocyte globulins. Human Immunology, 2011, 72, 1060-1063.	2.4	4
89	Conversion From Belatacept to Another Immunosuppressive Regimen in Maintenance Kidney-Transplantation Patients. Kidney International Reports, 2020, 5, 2195-2201.	0.8	4
90	Six-month cardiovascular changes in cyclosporine-treated recipients of corneal grafts: serial baroreflex responses. Transplant International, 2004, 17, 325-33.	1.6	3

#	Article	IF	CITATIONS
91	Cytomegalovirus and Thromboembolism in Renal Transplantation. Transplantation, 2005, 79, 248-249.	1.0	3
92	Outcomes of Older Patients (≥60 years) with New-Onset Idiopathic Nephrotic Syndrome Receiving Immunosuppressive Regimen: A Multicentre Study of 116 Patients. Journal of Clinical Medicine, 2019, 8, 298.	2.4	3
93	Living kidney donor evaluation for all candidates with normal estimated GFR for age. Transplant International, 2021, 34, 1123-1133.	1.6	3
94	Characteristics of T- and NK-cell Lymphomas After Renal Transplantation: A French National Multicentric Cohort Study. Transplantation, 2021, 105, 1858-1868.	1.0	3
95	BK virusâ€associated urologic complications. Pediatric Transplantation, 2007, 11, 821-822.	1.0	2
96	G-765C COX-2 Gene Promoter Polymorphism and Risk of Atherosclerosis After Kidney Transplantation. Transplantation, 2009, 88, 851-852.	1.0	2
97	Serum immunoglobulin G levels and peritonitis in peritoneal dialysis patients. Journal of Nephrology, 2015, 28, 511-515.	2.0	2
98	Bictegravir/emtricitabine/tenofovir alafenamide combination in the management of kidney transplant patients with HIV receiving immunosuppressants. Journal of Chemotherapy, 2022, 34, 199-202.	1.5	2
99	NEW-ONSET DIABETES AFTER TRANSPLANTATION: ONE POINT TO CONSIDER. Transplantation, 2004, 77, 1130-1131.	1.0	1
100	CD4 T Lymphopenia, Thymic Function, Homeostatic Proliferation and Late Complications Associated with Kidney Transplantation. , 2013, , .		1
101	Pretransplant coronary artery disease screening is still valid. Kidney International, 2021, 99, 772.	5.2	1
102	Should vaccination against COVID-19 be mandated in patients on the transplant waiting list?. Kidney International, 2021, 100, 939-940.	5.2	1
103	Potential influence of dialysis modality on post-transplantation diabetes mellitus risk. Nephrology Dialysis Transplantation, 2011, 26, 2063-2063.	0.7	Ο
104	The Role of CMV and EBV Renal Allograft Loss. American Journal of Transplantation, 2013, 13, 2230-2230.	4.7	0
105	CMV and Cardiovascular Disease: Reply. Journal of Infectious Diseases, 2013, 208, 1349-1350.	4.0	Ο
106	Portable low-flow daily home haemodialysis monitor to cope with the COVID-19 outbreak. Nephrology Dialysis Transplantation, 2020, 35, 2200-2202.	0.7	0
107	A simple score to predict early death after kidney transplantation. European Journal of Clinical Investigation, 2020, 50, e13312.	3.4	0
108	Genetic determinant of thymopoiesis and clinical outcomes in renal transplantation. Nephrology Dialysis Transplantation, 2021, 36, 2345-2347.	0.7	0

#	Article	IF	CITATIONS
109	Polyomavirus in a Lung Transplant Patient. Archives of Pathology and Laboratory Medicine, 2005, 129, 976-976.	2.5	0
110	Prevalence and clinical significance of antiphospholipid antibodies in renal transplant recipients. Transplantation, 1998, 65, S149.	1.0	0